Neuroscience Laboratory, Hugo Moser Research Institute, Kennedy Krieger Institute, Baltimore, Maryland.
Department of Neurological Surgery, University of California San Francisco, San Francisco, California.
Biol Psychiatry. 2020 May 1;87(9):829-842. doi: 10.1016/j.biopsych.2019.12.025. Epub 2020 Jan 10.
Loss-of-function SYNGAP1 mutations cause a neurodevelopmental disorder characterized by intellectual disability and epilepsy. SYNGAP1 is a Ras GTPase-activating protein that underlies the formation and experience-dependent regulation of postsynaptic densities. The mechanisms that contribute to this proposed monogenic cause of intellectual disability and epilepsy remain unresolved.
We established the phenotype of the epileptogenesis in a Syngap1 mouse model using 24-hour video electroencephalography (vEEG)/electromyography recordings at advancing ages. We administered an acute low dose of perampanel, a Food and Drug Administration-approved AMPA receptor (AMPAR) antagonist, during a follow-on 24-hour vEEG to investigate the role of AMPARs in Syngap1 haploinsufficiency. Immunohistochemistry was performed to determine the region- and location-specific differences in the expression of the GluA2 AMPAR subunit.
A progressive worsening of the epilepsy with emergence of multiple seizure phenotypes, interictal spike frequency, sleep dysfunction, and hyperactivity was identified in Syngap1 mice. Interictal spikes emerged predominantly during non-rapid eye movement sleep in 24-hour vEEG of Syngap1 mice. Myoclonic seizures occurred at behavioral-state transitions both in Syngap1 mice and during an overnight EEG from a child with SYNGAP1 haploinsufficiency. In Syngap1 mice, EEG spectral power analyses identified a significant loss of gamma power modulation during behavioral-state transitions. A significant region-specific increase of GluA2 AMPAR subunit expression in the somas of parvalbumin-positive interneurons was identified.
Acute dosing with perampanel significantly rescued behavioral state-dependent cortical gamma homeostasis, identifying a novel mechanism implicating Ca-impermeable AMPARs on parvalbumin-positive interneurons underlying circuit dysfunction in SYNGAP1 haploinsufficiency.
功能丧失性 SYNGAP1 突变导致一种神经发育障碍,其特征为智力障碍和癫痫。SYNGAP1 是一种 Ras GTP 酶激活蛋白,为突触后密度的形成和经验依赖性调节提供基础。导致这种遗传性智力障碍和癫痫的机制仍未解决。
我们通过在年龄增长过程中进行 24 小时视频脑电图(vEEG)/肌电图记录,在 Syngap1 小鼠模型中建立了癫痫发生的表型。我们在后续的 24 小时 vEEG 中给予急性低剂量的 perampanel(一种美国食品和药物管理局批准的 AMPA 受体(AMPAR)拮抗剂),以研究 AMPAR 在 Syngap1 杂合不足中的作用。我们进行免疫组织化学染色,以确定 GluA2 AMPAR 亚基在表达上的区域和位置特异性差异。
在 Syngap1 小鼠中发现癫痫逐渐加重,出现多种癫痫发作表型、发作间期棘波频率、睡眠功能障碍和多动。在 Syngap1 小鼠的 24 小时 vEEG 中,发作间期棘波主要出现在非快速眼动睡眠期间。在 Syngap1 小鼠中,肌阵挛性发作发生在行为状态转换期间,在具有 SYNGAP1 杂合不足的儿童的整夜 EEG 中也发生在行为状态转换期间。在 Syngap1 小鼠中,脑电图频谱功率分析发现行为状态转换期间的伽马功率调制显著丧失。还发现在具有 GABA 能中间神经元特征的 Parvalbumin 阳性中间神经元的胞体中,GluA2 AMPAR 亚基表达显著增加。
急性给予 perampanel 可显著挽救行为状态依赖性皮质伽马平衡,确定了一种新的机制,涉及 Parvalbumin 阳性中间神经元上的 Ca2+不可渗透的 AMPAR,为 SYNGAP1 杂合不足中的回路功能障碍提供了基础。